Sun Pharmaceutical Industries (SUNPHARMA) Weekly Analysis
Price & Volume
The stock price declined by 3.29% this week, ending at 1620.4. Trading activity remained steady with a slight increase in total volume of 5.88% compared to the previous week. The price currently sits below both its 50-day and 200-day moving averages, indicating a downward trend relative to these long-term price benchmarks.
Technicals
This week, the asset closed at 1620.4, reflecting a 3.29% decline. The Relative Strength Index (RSI), which measures the speed and change of price movements, stands at 33.27, indicating weak momentum. The Moving Average Convergence Divergence (MACD), a trend-following indicator showing the relationship between two price averages, shows the MACD line at -25.80, remaining below the signal line. Bollinger Band width, representing volatility or price dispersion, is at 10.56%. The current technical regime is characterized by downward-sloping moving averages and weakening momentum, with price action remaining below key trend benchmarks.
Fundamentals
Sun Pharmaceutical Industries shows consistent growth, with revenue reaching ₹52,578 in Mar 2025, marking an 8.4% YoY increase. Net profit grew by 14.1% YoY to ₹10,965, reflecting strong earnings performance. The company maintains a solid profitability profile, with a TTM EBITDA margin of 31.6%, indicating efficient core operations. Furthermore, the firm exhibits a disciplined balance sheet, evidenced by a low net debt to EBITDA ratio of 0.1 as of Mar 2025. These metrics, supported by a 3-year net profit CAGR of 47.9%, highlight a period of sustained financial expansion and operational efficiency for the business.
News
Between April 20 and April 26, 2026, Sun Pharmaceutical Industries Limited faced significant market attention regarding reports of a potential $13 billion acquisition of Organon. While some analysts highlighted the strategic benefits of this move as part of a broader shift toward overseas expansion and away from traditional generics, the news triggered a decline in Sun Pharma shares of over 3% by April 24. Concurrently, the company experienced shifts in technical momentum, leading to a downgrade to a hold rating by Markets Mojo on April 22 due to mixed valuation signals. These developments reflected investor caution regarding the scale of the proposed deal and the company's evolving international growth strategy.
Events
Sun Pharmaceutical Industries Limited has incorporated a wholly owned subsidiary, Sun Pharma America, Inc., in the United States for internal group structuring purposes.
Sun Pharmaceutical Industries Limited shareholders have approved the ratification of the FY 2025-26 cost auditor remuneration, an alteration to the Memorandum of Association, and the reappointment of Dr. Pawan Goenka as an Independent Director for a second five-year term.
Sun Pharmaceutical Industries Limited has clarified that recent media reports regarding a $12 billion deal with Organon are speculative and do not represent a material event requiring disclosure.
Clarification sought from Sun Pharmaceutical Industries Ltd 10 Apr - Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting …
Sun Pharmaceutical Industries Limited published newspaper advertisements on 8 April 2026 regarding the process for Postal Ballot and e-voting, providing shareholders with necessary information to participate in the voting process.
CRISIL Ratings has reaffirmed Sun Pharmaceutical Industries Limited's long-term and short-term ratings at 'CRISIL AAA/Stable/CRISIL A1+', reflecting the company's strong market leadership, robust financial risk profile, and healthy specialty product growth. This stability provides shareholders with confidence in the company's ability to manage its capital expenditure and maintain a strong liquidity position despite ongoing regulatory and competitive pressures.
ICRA has issued a credit rating rationale report dated March 3, 2026, which provides updated financial analysis relevant for stakeholders assessing the company's credit risk profile.
Sun Pharmaceutical Industries Limited shareholders have approved the ratification of the FY 2025-26 cost auditor remuneration, an alteration to the Memorandum of Association, and the reappointment of Dr. Pawan Goenka as an Independent Director for a second five-year term.
Sun Pharmaceutical Industries Limited has clarified that recent media reports regarding a $12 billion deal with Organon are speculative and do not represent a material event requiring disclosure.
Clarification sought from Sun Pharmaceutical Industries Ltd 10 Apr - Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting …
Sun Pharmaceutical Industries Limited published newspaper advertisements on 8 April 2026 regarding the process for Postal Ballot and e-voting, providing shareholders with necessary information to participate in the voting process.
CRISIL Ratings has reaffirmed Sun Pharmaceutical Industries Limited's long-term and short-term ratings at 'CRISIL AAA/Stable/CRISIL A1+', reflecting the company's strong market leadership, robust financial risk profile, and healthy specialty product growth. This stability provides shareholders with confidence in the company's ability to manage its capital expenditure and maintain a strong liquidity position despite ongoing regulatory and competitive pressures.
ICRA has issued a credit rating rationale report dated March 3, 2026, which provides updated financial analysis relevant for stakeholders assessing the company's credit risk profile.
Weekly Snapshot
Highlights
- Sun Pharma shares declined by 3.29% this week, closing at 1620.4 as trading volume increased by 5.88%.
- The Relative Strength Index (RSI), which measures the speed and change of price movements, fell to 33.27, indicating weak momentum.
- The company incorporated a new wholly owned subsidiary, Sun Pharma America, Inc., in the United States for internal group structuring.
- Shareholders approved the reappointment of Dr. Pawan Goenka as an Independent Director and ratified cost auditor remuneration.
- Media reports regarding a $12 billion deal with Organon were clarified by the company as speculative and not a material event.
What This Means
Sun Pharma experienced a week of downward price pressure and weakening technical momentum, with the stock trading below its 50-day and 200-day moving averages. While the company maintains strong fundamental performance, including a 31.6% TTM EBITDA margin and consistent revenue growth, market sentiment was influenced by speculation regarding a potential acquisition. The company officially clarified that reports of a large deal with Organon were speculative. Additionally, corporate governance activities concluded with the approval of board appointments and internal restructuring through a new US subsidiary.
Latest Quarter Info
The quarter ending December 2025 reflects a period of consistent operational expansion, characterized by a healthy alignment between revenue growth and bottom-line performance. Revenue demonstrated solid momentum, posting a 7.2% sequential increase and a 13.5% year-over-year rise, indicating sustained demand. Profitability remains robust, with an operating margin of 32% highlighting effective cost management relative to top-line output. Net profit growth outpaced revenue growth on a year-over-year basis, rising by 16.1%, which suggests improved operational leverage. With an earnings per share of 14.04 and a stable tax profile, the company maintains a disciplined financial structure. Overall, the combination of double-digit year-over-year gains in both revenue and net profit points to a stable trajectory, supported by consistent margin maintenance and controlled expenditure levels throughout the quarter.